<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01448486</url>
  </required_header>
  <id_info>
    <org_study_id>11/033</org_study_id>
    <secondary_id>IISP 37693</secondary_id>
    <nct_id>NCT01448486</nct_id>
  </id_info>
  <brief_title>A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV</brief_title>
  <acronym>HANDral</acronym>
  <official_title>A Randomised Controlled Clinical Trial of the Efficacy of HAART Intensification With Raltegravir in HIV Virally Suppressed Patients With Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Vincent's Hospital, Sydney</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St Vincent's Hospital, Sydney</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV related cognitive impairment still occurs despite highly active antiretroviral therapy
      (HAART). HIV disease affects the brain in 20-40% of patients with advancing HIV disease
      leading to varying degrees of cognitive impairment, recently termed HIV associated
      neurocognitive disorders (HAND).

      HAND may occur in patients who are virally suppressed in both blood and CSF. Patients with
      HIV Associated Neurological Disorders (HAND) who are virally suppressed in both their blood
      and cerebrospinal fluid (CSF), whilst on a highly active antiretroviral therapy (HAART)
      regimen may have significant cognitive improvement with HAART intensification with the
      medication RaltegravirÍ¾ compared to those who remain on their existing regimen.

      This study will be a prospective, interventional, randomised and unblinded controlled
      clinical trial. The aim of this study will be to determine whether HAART intensification with
      the medication Raltegravir, leads to significant improvement in HIV associated neurological
      disorders (HAND).

      Patients with the recent progression (within 6 months) of HAND (validated by
      neuropsychological assessment) on HAART who are virally suppressed (&lt;50 copies per ml) in
      blood and CSF will be randomised to have their existing HAART regimen intensified with
      raltegravir 400mg twice daily, or not. The control arm will remain on their medication
      regimen as prescribed. The target is to enrol 110 patients into the control group, and 110
      patients into the Raltegravir intensification group.

      Patients will undergo baseline neuropsychological testing, MRI, blood tests, and cerebral
      spinal fluid (CSF) tests (via a lumbar puncture). The methods used to determine the
      effectiveness of adding Raltegravir, will include further neuropsychological testing at 6
      months; and neuropsychological testing, MRI and CSF assessment at 12 months.
      Neuropsychological testing completed at 6 and 12 months will be completed by a &quot;blind
      assessor&quot;, in that they will have no knowledge of which arm (treatment or control) the
      participant is enrolled in.

      An evaluation (neuropsychological testing) will be performed should the patient deteriorate
      during the course of the study, as recognised by the patient's managing physician. The
      decision of the Antiretroviral medication regimen to be used in such a case will be
      determined by the managing physician. At the end of the study protocol (12 months) the
      patient's HAART therapy will be managed by their primary physician.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding withdrawn based on unacceptably slow recruitment rate.
  </why_stopped>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurocognitive Function</measure>
    <time_frame>Baseline, 6 months and 12 months</time_frame>
    <description>Change in overall neurocognitive performance, defined as a global neurocognitive z-score, over the study time-period (baseline, 6-months, 12-months). To derive this score, 1) raw scores obtained from a 5-domain brief neurocognitive battery were converted to age-corrected z-scores (M=0, SD=1) and 2) the set of individual subtest z-scores were averaged to generate a single composite (global) z-score for each subject. Lower (negative) scores therefore indicate greater levels of cognitive impairment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal Fluid</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>To determine if there is improvement in CSF neopterin concentrations with the addition of Raltegravir.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Human Immunodeficiency Virus (HIV)</condition>
  <condition>HIV Associated Neurocognitive Disorders (HAND)</condition>
  <arm_group>
    <arm_group_label>Standard of Care HAART</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART) with the addition of Raltegravir 400 mg twice daily (BID).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Oral raltegravir, 400 mg tablet, twice daily for one year.</description>
    <arm_group_label>Raltegravir</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV positive

          -  On HAART, with plasma HIV viral load &lt; 50 copies/ml for previous 12 months or more

          -  Able to provide informed consent

          -  HAND diagnosis, with symptom progression within previous 6 months (while on existing
             HAART regimen)

        Exclusion Criteria:

          -  Non-HIV related neurological disorders and active CNS opportunistic infection (as
             assessed by full blood count, electrolytes, creatinine, glucose, LFT's, cryptococcal
             antigen, VDRL, MRI brain scan and CSF fluid analysis for cell count, protein, glucose,
             culture, VDRL and cryptococcal antigen)

          -  Psychiatric disorders on the psychotic axis

          -  Current major depression

          -  Current substance use disorder, or severe substance use disorders within 12 months of
             study entry

          -  Active HCV (detectable HCV RNA)

          -  History of loss of consciousness &gt; 1 hour

          -  Non-proficient in English

          -  Medications known to pharmacologically interact with ARV's

          -  Currently taking an Integrase Inhibitor

          -  Pregnancy (as assessed by the urine pregnancy test)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce J Brew, MBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Vincent's Hospital, Sydney</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2011</study_first_submitted>
  <study_first_submitted_qc>October 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2011</study_first_posted>
  <results_first_submitted>November 13, 2013</results_first_submitted>
  <results_first_submitted_qc>November 13, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 3, 2014</results_first_posted>
  <last_update_submitted>May 19, 2016</last_update_submitted>
  <last_update_submitted_qc>May 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St Vincent's Hospital, Sydney</investigator_affiliation>
    <investigator_full_name>Bruce Brew</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HAND</keyword>
  <keyword>Human Immunodeficiency Virus</keyword>
  <keyword>Raltegravir</keyword>
  <keyword>HIV Associated Neurocognitive Disorders</keyword>
  <keyword>Neuro-HAART</keyword>
  <keyword>Neurocognitive</keyword>
  <keyword>Neurology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Neurocognitive Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period from October 2011 to October 2013. Participants were known patients of the PI or referred from local tertiary sexual health clinics by associate investigators.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Raltegravir</title>
          <description>Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART) with the addition of Raltegravir 400 mg twice daily (BID).
Raltegravir : Oral raltegravir, 400 mg tablet, twice daily for one year.</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care HAART</title>
          <description>Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raltegravir</title>
          <description>Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART) with the addition of Raltegravir 400 mg twice daily (BID).
Raltegravir : Oral raltegravir, 400 mg tablet, twice daily for one year.</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care HAART</title>
          <description>Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.0" spread="8.7"/>
                    <measurement group_id="B2" value="59.3" spread="4.9"/>
                    <measurement group_id="B3" value="55.7" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Neurocognitive Function</title>
        <description>Change in overall neurocognitive performance, defined as a global neurocognitive z-score, over the study time-period (baseline, 6-months, 12-months). To derive this score, 1) raw scores obtained from a 5-domain brief neurocognitive battery were converted to age-corrected z-scores (M=0, SD=1) and 2) the set of individual subtest z-scores were averaged to generate a single composite (global) z-score for each subject. Lower (negative) scores therefore indicate greater levels of cognitive impairment.</description>
        <time_frame>Baseline, 6 months and 12 months</time_frame>
        <population>Study was terminated prematurely with an incomplete study dataset any before any meaningful statistical analysis of the data (including change over the study time-points) could be performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART) with the addition of Raltegravir 400 mg twice daily (BID).
Raltegravir : Oral raltegravir, 400 mg tablet, twice daily for one year.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care HAART</title>
            <description>Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART).</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Function</title>
          <description>Change in overall neurocognitive performance, defined as a global neurocognitive z-score, over the study time-period (baseline, 6-months, 12-months). To derive this score, 1) raw scores obtained from a 5-domain brief neurocognitive battery were converted to age-corrected z-scores (M=0, SD=1) and 2) the set of individual subtest z-scores were averaged to generate a single composite (global) z-score for each subject. Lower (negative) scores therefore indicate greater levels of cognitive impairment.</description>
          <population>Study was terminated prematurely with an incomplete study dataset any before any meaningful statistical analysis of the data (including change over the study time-points) could be performed.</population>
          <units>Global Neurocognitive Z-Score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.29"/>
                    <measurement group_id="O2" value="-0.39" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.12"/>
                    <measurement group_id="O2" value="-0.48" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.46"/>
                    <measurement group_id="O2" value="-0.54" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebrospinal Fluid</title>
        <description>To determine if there is improvement in CSF neopterin concentrations with the addition of Raltegravir.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Study was terminated prematurely with an incomplete study dataset before any meaningful analyses of the data could be conducted. CSF was not collected at 12 months for n=1 raltegravir and n=1 control who refused lumbar puncture.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART) with the addition of Raltegravir 400 mg twice daily (BID).
Raltegravir : Oral raltegravir, 400 mg tablet, twice daily for one year.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care HAART</title>
            <description>Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART).</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebrospinal Fluid</title>
          <description>To determine if there is improvement in CSF neopterin concentrations with the addition of Raltegravir.</description>
          <population>Study was terminated prematurely with an incomplete study dataset before any meaningful analyses of the data could be conducted. CSF was not collected at 12 months for n=1 raltegravir and n=1 control who refused lumbar puncture.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.67" spread="2.91"/>
                    <measurement group_id="O2" value="34.00" spread="16.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.00" spread="7.00"/>
                    <measurement group_id="O2" value="12.00" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Raltegravir</title>
          <description>Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART) with the addition of Raltegravir 400 mg twice daily (BID).
Raltegravir : Oral raltegravir, 400 mg tablet, twice daily for one year.</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care HAART</title>
          <description>Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Flu-like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to incomplete dataset with sample size too small to produce any meaningful statistical analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prof. Bruce Brew</name_or_title>
      <organization>St. Vincent's Hospital, Sydney</organization>
      <phone>61 2 8382 1111 ext 4100</phone>
      <email>b.brew@unsw.edu.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

